Drug Trial Radar · NCT07804186
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Sep 4, 2026
Primary completion
Mar 2034
Study completion Apr 2034
Sponsor
- Lead sponsor
- IDEAYA BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Sep 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
Conditions
- Uveal Melanoma
Interventions
DarovasertibDrug
Oral, selectively targets key proteins
Crizotinib (Xalkori)Drug
Oral small molecule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median relapse-free survivalTime frame: Approximately 5 years
Locations
29 sites in 6 countries. Site status is shown where the registry gives one.
Honor Health Research Institute
Scottsdale, Arizona · Recruiting
UCLA Medical Center
Los Angeles, California · Not yet recruiting
Angeles Clinic
Los Angeles, California · Not yet recruiting
University of California, San Diego
San Diego, California · Not yet recruiting
Sutter Health CPMC
San Francisco, California · Not yet recruiting
University of California, San Francisco
San Francisco, California · Not yet recruiting
University of Miami
Miami, Florida · Not yet recruiting
USF Health Eye Institute
Tampa, Florida · Not yet recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Not yet recruiting
Cancer Hematology Centers Western Michigan
Grand Rapids, Michigan · Not yet recruiting
Columbia University - Herbert Irving Comprehensive Cancer Center
New York, New York · Not yet recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Not yet recruiting
Northwell Health
New York, New York · Not yet recruiting
Duke Cancer Center
Raleigh, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Wills Eye Hospital at Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
Sarah Cannon Research Institute (SCRI)
Nashville, Tennessee · Recruiting
The University of Texas Southwestern Medical Center
Dallas, Texas · Not yet recruiting
UT MD Anderson Cancer Center
Houston, Texas · Not yet recruiting
University of Wisconsin Health
Madison, Wisconsin · Not yet recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Not yet recruiting
Alfred Health
Melbourne, Victoria, Australia · Not yet recruiting
Universite de Montreal - Centre de Recherche du Centre Hospitalier de l'Universite de Montreal
Montréal, Ontario, Canada · Not yet recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Hadassah Medical Center
Jerusalem, Israel · Not yet recruiting
Sheba Medical Center
Ramat Gan, Israel · Not yet recruiting
University of Zurich Hospital
Zurich, Switzerland · Not yet recruiting
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom · Not yet recruiting
Mount Vernon Hospital
Northwood, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.